Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Phase 3

Active, not recruiting

Conditions: Urinary Bladder Cancer, Muscle-invasive

Interventions: Drug: Enfortumab Vedotin
Drug: Pembrolizumab
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

First Posted Date: 2019-04-23

Last Posted Date: 2025-01-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 857

Registration Number: NCT03924895

Locations: 🇨🇦
Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada
🇺🇸
University of Chicago ( Site 0068), Chicago, Illinois, United States
🇪🇸
Hospital Universitario San Carlos ( Site 0678), Madrid, Spain

and more 239 locations

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: V114
Biological: Prevnar 13™
Biological: PNEUMOVAX™23

First Posted Date: 2019-04-19

Last Posted Date: 2023-06-07

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 407

Registration Number: NCT03921424

Locations: 🇹🇭
Faculty of Medicine - Khon Kaen University-Pediatrics ( Site 0063), Amphoe Mueang, Khon Kaen, Thailand
🇿🇦
Wits Reproductive Health and HIV Institute (WRHI) ( Site 0043), Johannesburg, Gauteng, South Africa
🇿🇦
Perinatal HIV Research Unit ( Site 0042), Johannesburg, Gauteng, South Africa

and more 10 locations

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Phase 1

Active, not recruiting

Conditions: Neoplasms

Interventions: Biological: MK-0482
Biological: pembrolizumab
Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2019-04-17

Last Posted Date: 2025-06-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 230

Registration Number: NCT03918278

Locations: 🇺🇸
Next Oncology ( Site 0001), San Antonio, Texas, United States
🇨🇦
Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario, Canada
🇨🇦
BC Cancer - Vancouver Center ( Site 0010), Vancouver, British Columbia, Canada

and more 13 locations

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Phase 4

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Neostigmine + Glycopyrrolate
Drug: Sugammadex 2 mg/kg
Drug: Sugammadex 4 mg/kg
Drug: Neostigmine + Atropine

First Posted Date: 2019-04-09

Last Posted Date: 2023-10-02

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 137

Registration Number: NCT03909165

Locations: 🇳🇱
University Medical Center Groningen ( Site 4227), Groningen, Netherlands
🇳🇱
Wilhelmina Kinderziekenhuis ( Site 4228), Utrecht, Netherlands
🇺🇸
Variety Children's Hospital D.B.A. Nicklaus Children's Hospital ( Site 3019), Miami, Florida, United States

and more 36 locations

Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

Phase 3

Completed

Conditions: Papillomavirus Infections

Interventions: Biological: V503

First Posted Date: 2019-04-04

Last Posted Date: 2025-03-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1990

Registration Number: NCT03903562

Locations: 🇨🇳
Shaoxing keqiao center for disease prevention and control ( Site 0001), Shaoxing, Zhejiang, China
🇨🇳
Kaihua country Center for Disease Control and Prevention ( Site 0002), Quzhou, Zhejiang, China

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Phase 3

Completed

Conditions: Urothelial Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Lenvatinib
Drug: Placebo for lenvatinib

First Posted Date: 2019-04-01

Last Posted Date: 2025-06-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 505

Registration Number: NCT03898180

Locations: 🇺🇸
Seattle Cancer Care Alliance ( Site 0003), Seattle, Washington, United States
🇺🇸
Northwest Georgia Oncology Centers PC ( Site 0707), Marietta, Georgia, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0002), New York, New York, United States

and more 191 locations

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Phase 3

Completed

Conditions: Pneumococcal Vaccines
Pneumococcal Infections

Interventions: Biological: Prevnar 13™
Biological: V114
Biological: RotaTeq™
Biological: Pentacel™
Biological: RECOMBIVAX HB™
Biological: VAQTA™
Biological: MMR II™
Biological: VARIVAX™
Biological: HIBERIX™

First Posted Date: 2019-03-28

Last Posted Date: 2023-07-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1720

Registration Number: NCT03893448

Locations: 🇺🇸
Kentucky Pediatric/Adult Research Inc ( Site 0136), Bardstown, Kentucky, United States
🇺🇸
Capitol Pediatrics & Adolescent Center ( Site 0223), Raleigh, North Carolina, United States
🇺🇸
Holston Medical Group ( Site 0165), Kingsport, Tennessee, United States

and more 78 locations

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: V114
Biological: Prevnar 13®

First Posted Date: 2019-03-22

Last Posted Date: 2023-01-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 606

Registration Number: NCT03885934

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny ( Site 0207), Wroclaw, Poland
🇷🇺
Research Institute of Children Infections ( Site 0301), Saint Petersburg, Russian Federation
🇷🇺
Children s City Polyclinic No. 45 of the Nevsky District ( Site 0312), St.Petersburg, Russian Federation

and more 23 locations

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

Phase 3

Completed

Conditions: Endometrial Neoplasms

Interventions: Drug: Lenvatinib
Drug: Paclitaxel
Drug: Carboplatin
Biological: Pembrolizumab

First Posted Date: 2019-03-21

Last Posted Date: 2025-02-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 842

Registration Number: NCT03884101

Locations: 🇺🇸
UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233), Los Angeles, California, United States
🇺🇸
University of Rochester ( Site 0238), Rochester, New York, United States
🇧🇷
Faculdade de Medicina da Universidade Federal de Minas Gerais ( Site 2708), Belo Horizonte, Minas Gerais, Brazil

and more 192 locations

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Phase 1

Completed

Conditions: Obstructive Sleep Apnea (OSA)

Interventions: Drug: Gefapixant
Drug: Placebo

First Posted Date: 2019-03-20

Last Posted Date: 2024-11-04

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 24

Registration Number: NCT03882801

Locations: 🇺🇸
MD Clinical ( Site 0004), Hallandale Beach, Florida, United States
🇺🇸
Clinilabs, Inc. ( Site 0005), New York, New York, United States
🇧🇪
Universitair Ziekenhuis Gent ( Site 0012), Gent, Belgium

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy